Immunotherapy Europe Companies - Top Immunotherapy Solution Companies In Europe
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Oblique Therapeutics AB: Tailored High Affinity Functional Antibodies Against Hard To Drug Targets In Cancer And Pain
line

Top 10 Immunotherapy Solution Companies in Europe - 2021

line

In the last decade, Immunotherapy has become a viable treatment option for many cancer patients. Unlike radiation and chemotherapy, Immunotherapy does not target cancer itself. Instead, it enables a patient’s own immune system to attack the disease. In most cases, immune-based treatments stimulate T cells, a specialised type of immune cell, to fight cancer. Further, Immunotherapy drugs called immune checkpoint inhibitors accomplish this by blocking checkpoint proteins that live on the surface of T cells and act as “brakes” to prevent the T cells from accidentally attacking healthy cells. Now a standard treatment for a growing list of cancers, checkpoint inhibitors have proven effective for treating several types of cancers, including melanoma, small cell lung cancer, non-small cell lung cancer, lymphoma and more. To summarise, Immunotherapy for cancer treatment magnifies the body’s natural immune response to cancer, with a side effect profile different from regular chemotherapy.

The science is evolving in terms of helping us identify which patients will benefit from Immunotherapy with the advantage that those who respond to Immunotherapy are likely to have sustained and durable responses. Consequently, such innovations pave the way for the decentralised manufacturing of novel cell therapies. Right now, amid a wide variety of vendors entering the industry with a set of advanced and integrated immunotherapy solutions, we are helping companies navigate through the best-of-breed organisations. The enlisted companies are transforming immunotherapy processes and treatments at the intersection of various disruptive technologies. Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for aspiring CIOs.

We present to you Pharma Tech Outlook’s “Top 10 Immunotherapy Solution Providers in Europe – 2021.”

    Top Immunotherapy Solution Companies in Europe

  • Offers technology platforms that modulate immune responses based on antigen-specific cells of the innate immune system.

    equaly.be

  • Oblique Therapeutics AB is an innovative biotech company that strives to increase the bandwidth of antibody therapeutics, focusing on pain and aggressive metastatic cancer

    obliquet.com

  • BIOMUNEX PHARMACEUTICALS

    BIOMUNEX PHARMACEUTICALS

    BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough immunotherapies using its Unique BiXAb® technology to create next generation bi- and multi-specific antibodies. Its disruptive biological approaches target a number of cancer types, in particular where there are unmet medical needs. BIOMUNEX are committed to provide oncologists and patients with immunotherapies that are novel, efficacious and prolong life expectancy

  • DBV Technologies

    DBV Technologies

    DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. The company is on a mission to advance epicutaneous immunotherapy using innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives its commitment to the advancement of treatments for patients and their families. That is why DBV is investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin

  • Glycostem Therapeutics

    Glycostem Therapeutics

    Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for industrial scale-up

  • Inmunotek

    Inmunotek

    INMUNOTEK is a pharmaceutical laboratory that researches, develops, manufactures and markets therapeutic vaccines in the fields of allergy, infectious diseases and cancer. It also manufactures and markets healthcare products and medical devices in more than 50 countries through subsidiaries, delegations and exclusive distributors

  • Innate Pharma

    Innate Pharma

    Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca

  • Merck Group

    Merck Group

    Merck delivers personalized treatments for serious diseases and enable people to achieve their dream of becoming parents. The group empowers scientific community with tools, services and digital platform that makes research simpler, more exact, delivering breakthroughs more quickly. Merck's solutions accelerate access to health by assuring tests are accurate and the medicine they provide are legitimate

  • Novartis

    Novartis

    Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, Novartis use innovative science and digital technologies to create transformative treatments in areas of great medical need. In their quest to find new medicines, Novartis consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and Novartis is finding innovative ways to expand access to its latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world

  • Zelluna Immunotherapy

    Zelluna Immunotherapy

    Zelluna Immunotherapy is a company developing transformative T cell receptor (TCR) based cellular immunotherapies for the treatment of solid cancers. The company is developing a unique portfolio of tumor specific TCR’s that target the MHC class II pathway to broadly engage the host immune system to provide a safe, efficient and durable clinical response. The company is developing therapies based on the effector functions of autologous T cells (TCR-T) and allogeneic NK cells (TCR-NK). Both of these platforms have their unique advantages and provides the opportunity to attack cancers from multiple angles and improve access to these advanced therapies to a large patient population